Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 (MMA-101 Following Administration of SEL-110) in Pediatric Subjects With Mut Subtype Isolated Methylmalonic Acidemia (MMA)

Next Previous
X
Search
Trial Profile

Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 (MMA-101 Following Administration of SEL-110) in Pediatric Subjects With Mut Subtype Isolated Methylmalonic Acidemia (MMA)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 30 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autoimmune therapy Cartesian Therapeutics (Primary) ; Sel 302 (Primary)
  • Indications Methylmalonic acidaemia
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms reiMMAgine
  • Sponsors Selecta Biosciences

    • Most Recent Events

    • 24 Sep 2024 Status changed from suspended to withdrawn prior to enrolment based on sponsor's decision.
    • 04 May 2023 Status changed to suspended, according to a Selecta Biosciences media release.
    • 04 May 2023 According to a Selecta Biosciences media release, company will pause further development of its wholly-owned gene therapy programs, including the ongoing Phase 1/2 clinical trial of SEL-302. The Company is currently assessing ways to support further development of these programs through potential partnerships.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top